Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.55 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.53 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.53 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.53 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.53 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.53 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19011491 | 0.92 | PSEN1 (0.55) | HTR7PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21132496 | 0.92 | PSEN1 (0.55) | HTR7PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5885831 | 0.87 | HTR7 (0.55) | HTR7PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5885825 | 0.87 | HTR7 (0.55) | HTR7PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5886080 | 0.87 | PSEN1 (0.56) | HTR7PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5886085 | 0.87 | PSEN1 (0.56) | HTR7PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5885963 | 0.86 | BRD4 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6302770 | 0.86 | BRD4 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5885959 | 0.86 | BRD4 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5885854 | 0.83 | FKBP1A (0.56) | HTR7PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995182-B2 | 1-sulfonyl pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20030212066-A1 | 1-Sulfonyl pyrrolidine derivatives | MUTEL VINCENT (FR) | 2003-11-13 | — | — | US | disclosed |
| US-6589978-B2 | Therapy for nervous system disorders | HOFFMAN-LA ROCHE INC. | 2003-07-08 | — | — | US | disclosed |
| EP-1299383-A1 | SULFONYL-PYRROLIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-09 | — | — | EP | disclosed |
| US-20020019424-A1 | 1-sulfonyl pyrrolidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-14 | — | — | US | disclosed |
| WO-2002002554-A1 | SULFONYL-PYRROLIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212066-A1 | 1-Sulfonyl pyrrolidine derivatives | GRM1, GRM2, GRIN1 | HTR7 360/4885PSEN1 334/4885PSEN2 561/4885 |
| US-20020019424-A1 | 1-sulfonyl pyrrolidine derivatives | GRM1, GRM2, GRIN1 | HTR7 360/4885PSEN1 334/4885PSEN2 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.